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Background: HER2 is a known driver of breast cancer progres-
sion in 15–30% of primary breast carcinomas and an important
target for therapy. More recently, it was established that tran-
script splice variants of HER2, including delta16-HER2, herstatin,
p100 participate in malignant progression and drug resistance.
Exosomes are small vesicles of endocytic origin, which are
released by many different cell types and can be used as potential
novel biomarkers, since they contain DNA and RNA derived from
cancer cells. The aim of this study is to explore the use of
exosomes for detecting HER2 splice variants and compare levels
HER2 splice variants in cells and their exosomes.
Material and methods: Breast cancer cell lines MDA-MB-361,
MDA-MB- 231, MCF7, MCF7-Adr and BT549 were grown as mono-
layer cultures as recommended by American Type Culture Collec-
tion. The exosomes were isolated by an ultracentrifugation
protocol. Total RNA was isolated and cDNA was generated to be
used for classic PCR and SYBR Green I quantitative (q) PCR.
Results: We determined HER2 splice variants levels in MDA-
MB-361, MDA-MB-231 breast cancer cell lines and in exosomes
derived from MDA-MB-36. MDA-MB-361 cells expressed high
levels of full length HER2 mRNA, delta16-HER2 mRNA, whereas
no expression was detected in other cell lines. Exosomes derived
from MDA-MB-231 cells line were negative for Herstatin, delta16-
HER2 and p100 but positive for mRNA of full length HER2.
Conclusion: The absence of HER2 mRNA and splice variants in
MCF7, MCF7-Adr and BT549 cells lines corresponded to their
absence in exosomes. Although the other cell lines remain to be
examined, we speculate that exosomes will reflect the HER2
splice variants content present in the breast cancer cells.
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Genotoxic stress induces significant changes in expression
rates of regulatory proteins inside transformed cells. Since some
of these proteins are short-lived ones and they undergo rapid
proteasomal degradation, combined treatment with genotoxic
agent (doxorubicin) and proteasome inhibitor (bortezomib)
should launch accumulation of these proteins in cancer cells.
This accumulation is even more characteristic for the multiple
myeloma cells due to their high synthetic potential.
We investigated the pattern of regulatory proteins associated
with PSMA3 subunit of 20S proteasome core. PSMA3 is engaged
into ubiquitin-independent degradation of several proteins
known to contribute in cancer development (IjBa, p21WAF1/
CIP1). We suppose, that the proteins revealed may either be
directed to undergo ubiquitin-independent proteolysis, or possess
proteasome-regulating activity, and changes in their abundance
may not only serve as an evidence of some treatment-induced
changes, but also may be considered as biomarkers of the thera-
pies efficiency.
RPMI 8226 multiple myeloma cell line was used as a model
object. Before the actual treatment the proper apoptosis-
inducing concentrations of doxorubicin and bortezomib were
determined in order to avoid necrosis. PSMA3-interacting pro-
teins were isolated by incubation with GST-PSMA3 fusion protein
attached to glutathione sepharose beads, 2D-electrophoretically
separated and identified by MALDI TOF/TOF mass-spectrometry.
As a result we obtained heterogeneous list of proteins that can
be functionally divided into 12 subgroups: RNA turnover regula-
tors, chaperones and chaperonines, metabolic regulators, transla-
tion factors, cytoskeleton proteins, mitochondrial proteins,
transcriptional regulators, subunits of proteasomal regulatory
complexes, and several minor groups housing single members.
Due to their function and metabolism inside the cell some of
the identified proteins seem to be promising for the further inves-
tigation; among them are HuR, TUSC1 (Tumour Suppressor Can-
didate), several hnRNP representatives, numerous chaperones
(GRP78 in particular). Presence of these proteins was additionally
confirmed with immunoblotting assay, which pattern also gave
several promising guidelines for further elaboration of the data.
To exemplify, ELAVL1 (HuR) protein is known to be a protector
of mRNAs for c-myc, c-fos and some other proteins stabilising
them via binding AU-rich sequences in 30-UTR. As far as protea-
somes are also capable to recognise these motifs and moreover
possess RNAse activity, these two processes might compete
within the cell. According to immunoblotting patterns after drug
treatment of the cells HuR is significantly accumulated; this sup-
ports our assumption of it being degraded via proteasome-
independent proteolysis. Relying on the obtained data this
hypothesis and several others are being tested.
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Background: Breast cancer is the most common cause of death
from cancer among women aged 40–69 years. According to WHO,
about 1 million new cases of breast cancer are diagnosed annually
worldwide, and nearly 500,000 die from it. In Russia, more than
55,000 women are diagnosed with breast cancer annually, and
more than 22,000 die from it. Diagnosis and treatment of breast
cancer is the primary and important social and medical
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